DoD Funds Study For Early COVID-19 Symptom Detection Wearable mhealthintelligence.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mhealthintelligence.com Daily Mail and Mail on Sunday newspapers.
Startup gets Army funding to test wearable monitor for early Covid-19 detection
Remote monitoring startup BioIntelliSense and Royal Phillips received $2.8 million to test BioIntelliSense’s device for the early detection of Covid-19 symptoms. The startup received FDA clearance for its small, adhesive monitoring device last year.
Shares1
BioIntelliSense makes small, adhesive sensors that can monitor a patient’s vital signs. Photo credit: BioIntelliSense
Remote-monitoring startup BioIntelliSense received funding from the U.S. Army Medical Research and Development Command (USAMRDC) to see if its wearable sensor “sticker” could be used to detect Covid-19 symptoms early. The Golden, Colo.-based startup, and Royal Philips (NYSE: PHG), received a $2.8 million award to use wearable to identify Covid-19 cases before symptoms appear.
News Category Global Banking & Finance Reviews
Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.
Share this article
FORT WORTH, Texas, Dec. 22, 2020 /PRNewswire/
eTrueNorth the U.S.-based healthcare technology company that enables laboratory testing at retail pharmacies and enables all surge drive-through COVID-19 specimen collection sites, is partnering with the U.S. Department of Health and Human Services (HHS), the University of Wisconsin, Philips and BioIntelliSense Inc. under a US Army Medical Research Development Command (USAMRDC) funded award through the Medical Technology Enterprise Consortium (MTEC) to validate BioIntelliSense s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. This clinical trial is evaluating the use of wearable diagnostics for early identification and containment of COVID-19 cases.